The Medicines and Healthcare products Regulatory Agency (MHRA) has today (3 June 2026) authorised the medicine resmetirom (Rezdiffra) to treat adult patients with metabolic dysfunction-associated steatohepatitis (MASH). MASH is a liver disease where fat builds up in the liver, which can result in inflammation and damage to the liver cells. It is a result of the progression of nonalcoholic fatty liver disease […]